GenFleet Therapeutics (Shanghai) Inc. (HKG:2595)

Market Cap	12.64B
Revenue (ttm)	144.96M +24.4%
Net Income	-2.00B
EPS	-6.75
Shares Out	370.37M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,511,367
Open	34.08
Previous Close	34.12
Day's Range	31.00 - 36.00
52-Week Range	19.60 - 52.90
Beta	n/a
Analysts	Buy
Price Target	59.70 (+90.74%)
Earnings Date	Mar 24, 2026

About HKG:2595

GenFleet Therapeutics (Shanghai) Inc., a biopharmaceutical company, develops treatment options in the fields of oncology, autoimmune, and inflammatory diseases in the United States. The company develops GFH375, an orally bioavailable small molecule inhibitor of Kirsten rat sarcoma (KRAS) G12C in a Phase III trial for the treatment of pancreatic cancer, as well as in Phase II trials for the treatment of non-small cell lung cancer (NSCLC) and BTC, and in a Phase I trial for the treatment of solid tumors; GFH925, a small molecule selective inhibit...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2017
• Country: China
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2595

Financial Performance

In 2025, HKG:2595's revenue was 130.27 million, an increase of 24.42% compared to the previous year's 104.70 million. Losses were -1.79 billion, 164.8% more than in 2024.

Financial numbers in CNY